Health1 month ago
Goldman Sachs Downgrades Novo Nordisk on CagriSema Data
Investment firm Goldman Sachs has downgraded its rating for Danish pharmaceutical company Novo Nordisk from “buy” to “neutral” following disappointing results from a recent phase 3...